Market Size of Europe Cancer Vaccines Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 10.21 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Cancer Vaccines Market Analysis
The Europe Cancer Vaccines Market is expected to grow with a CAGR of 10.21% in the forecast period. The key factors propelling the growth of the market is the increasing number of cancer cases, and technological developments in cancer vaccines coupled with huge expenditure on cancer care.
The increasing incidence of cancer has been the major factor for the growth of the European cancer vaccine market. Cancer vaccines play a vital role in the maintenance of the immune system, as they are biological response modifiers. Moreover, healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side effects of the present therapies. Hence, the market for cancer vaccines is expected to grow at a high rate, during the forecast period.
According to the Global Cancer Observatory, the number of new incident cancer cases for the year 2018 was 4.2 million and the deaths exceeded 1.94 million in Europe. Thus, the growing incidence and prevalence of cancer are likely to drive the growth of the cancer therapeutics market in Europe during the forecast period.
Europe Cancer Vaccines Industry Segmentation
As per the scope of the report, cancer vaccines are defined as the vaccines developed to prevent or treat existing cancers, by strengthening the body's natural immune response system against cancer. These cancer vaccines belong to a class of substances, known as biological response modifiers. These modifiers work by stimulating or restoring the immune system's ability to fight against diseases.
| By Technology | |
| Recombinant Cancer Vaccines | |
| Whole-cell Cancer Vaccines | |
| Viral Vector and DNA Cancer Vaccines | |
| Other Technologies |
| By Treatment Method | |
| Preventive Vaccine | |
| Therapeutic Vaccine |
| By Application | |
| Prostate Cancer | |
| Cervical Cancer | |
| Other Applications |
| Geography | ||||||||
|
Europe Cancer Vaccines Market Size Summary
The Europe Cancer Vaccines Market is poised for significant expansion, driven by the rising incidence of cancer and advancements in vaccine technology. The market is characterized by its role in bolstering the immune system as biological response modifiers, addressing the substantial burden of cancer cases and the limitations of existing therapies. The increasing prevalence of cancer in Europe has underscored the importance of cancer vaccines, particularly preventive vaccines, which are designed to avert cancer in healthy individuals by targeting infectious agents linked to cancer development. The approval of vaccines such as Gardasil, Gardasil 9, and Cervarix by the European Medical Authority highlights the region's commitment to combating cervical and other HPV-related cancers.
The competitive landscape of the Europe Cancer Vaccines Market is dominated by major players like Amgen Inc., OSE Immunotherapeutics, Merck & Co. Inc., and Bristol-Myers Squibb, who hold significant market shares. These companies are pivotal in driving market growth through their innovative approaches and substantial investments in cancer care. The market's expansion is further supported by the increasing demand for cancer vaccines, fueled by the growing number of cancer cases in Europe. As a result, the Europe Cancer Vaccines Market is expected to experience robust growth, reflecting the region's proactive stance in addressing the cancer epidemic through advanced vaccine solutions.
Europe Cancer Vaccines Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Number of Cancer Cases
-
1.2.2 Technological Developments in Cancer Vaccines coupled with Huge Expenditure on Cancer Care
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Guidelines
-
1.3.2 Presence of Alternative Therapies
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Technology
-
2.1.1 Recombinant Cancer Vaccines
-
2.1.2 Whole-cell Cancer Vaccines
-
2.1.3 Viral Vector and DNA Cancer Vaccines
-
2.1.4 Other Technologies
-
-
2.2 By Treatment Method
-
2.2.1 Preventive Vaccine
-
2.2.2 Therapeutic Vaccine
-
-
2.3 By Application
-
2.3.1 Prostate Cancer
-
2.3.2 Cervical Cancer
-
2.3.3 Other Applications
-
-
2.4 Geography
-
2.4.1 Europe
-
2.4.1.1 Germany
-
2.4.1.2 United Kingdom
-
2.4.1.3 France
-
2.4.1.4 Italy
-
2.4.1.5 Spain
-
2.4.1.6 Rest of Europe
-
-
-
Europe Cancer Vaccines Market Size FAQs
What is the current Europe Cancer Vaccines Market size?
The Europe Cancer Vaccines Market is projected to register a CAGR of 10.21% during the forecast period (2024-2029)
Who are the key players in Europe Cancer Vaccines Market?
Merck & Co. Inc., Bristol-Myers Squibb, OSE Immunotherapeutics, Amgen Inc. and GlaxoSmithKline PLC are the major companies operating in the Europe Cancer Vaccines Market.
